Rhein modulates host purine metabolism in intestine through gut microbiota and ameliorates experimental colitis

被引:333
作者
Wu, Jiawei [1 ]
Wei, Zhonghong [1 ]
Cheng, Peng [1 ]
Qian, Cheng [1 ]
Xu, Fangming [1 ]
Yang, Yu [1 ]
Wang, Aiyun [1 ,2 ,3 ]
Chen, Wenxing [1 ,2 ,3 ]
Sun, Zhiguang [4 ]
Lu, Yin [1 ,2 ,3 ]
机构
[1] Nanjing Univ Chinese Med, Sch Pharm, Jiangsu Key Lab Pharmacolgy & Safety Evaluat Chin, Nanjing 210023, Peoples R China
[2] Nanjing Univ Chinese Med, State Key Lab Cultivat Base TCM Qual & Efficacy, Nanjing 210023, Peoples R China
[3] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Tradit Chinese Med, Nanjing, Peoples R China
[4] Nanjing Univ Chinese, Jiangsu Prov Chinese Med Hosp 2, Affiliated Hosp 2, Nanjing 210017, Peoples R China
基金
中国国家自然科学基金;
关键词
Rhein; DSS-induced colitis; purine metabolism; uric acid; gut microbiota; INDUCED MOUSE MODELS; XANTHINE-OXIDASE; PROBIOTICS; PROTECTS; DISEASES; BARRIER; HEALTH;
D O I
10.7150/thno.43528
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Gut microbiota, which plays a crucial role in inflammatory bowel diseases (IBD), might have therapeutic benefits for ulcerative colitis or Crohn's disease. Targeting gut microbiota represents a new treatment strategy for IBD patients. Rhein is one of the main components of rhubarb and exhibits poor oral bioavailability but still exerts anti-inflammatory effects in some diseases. Therefore, we investigated the effect of rhein on colitis and studied its possible mechanisms. Methods: The chronic mouse colitis model was induced by four rounds of 2% dextran sulfate sodium (DSS) treatment. The mice were treated with 50 mg/kg and 100 mg/kg rhein daily, body weight, colon length, histological score, inflammatory cytokines in serum or intestine, and fecal lipocalin 2 concentration were determined. Th17 cell, Th1 cell and Th2 cell infiltration in the mesenteric lymph node were analyzed by flow cytometry. Metabolic profiles were collected by non-targeted metabolomics and key metabolic pathways were identified using MetaboAnalyst 4.0. We also assessed intestinal barrier permeability and performed 16s rDNA sequencing. Lactobacillus sp. was cultured, and fecal microbiota transplantation (FMT) was employed to evaluate the contribution of gut microbiota. Results: Rhein could significantly alleviate DSS-induced chronic colitis. Uric acid was identified as a crucial modulator of colitis and rhein treatment led to decreased uric acid levels. We determined that rhein changed purine metabolism indirectly, while the probiotic Lactobacillus was involved in the regulation of host metabolism. Uric acid resulted in a worsened intestinal barrier, which could be rescued by rhein. We further confirmed that rhein-treated gut microbiota was sufficient to relieve DSS-induced colitis by FMT. Conclusion: We showed that rhein could modulate gut microbiota, which indirectly changed purine metabolism in the intestine and subsequently alleviated colitis. Our study has identified a new approach to the clinical treatment of colitis.
引用
收藏
页码:10665 / 10679
页数:15
相关论文
共 44 条
[21]   A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis [J].
Machiels, Kathleen ;
Joossens, Marie ;
Sabino, Joao ;
De Preter, Vicky ;
Arijs, Ingrid ;
Eeckhaut, Venessa ;
Ballet, Vera ;
Claes, Karolien ;
Van Immerseel, Filip ;
Verbeke, Kristin ;
Ferrante, Marc ;
Verhaegen, Jan ;
Rutgeerts, Paul ;
Vermeire, Severine .
GUT, 2014, 63 (08) :1275-1283
[22]   Regulation of uric acid metabolism and excretion [J].
Maiuolo, Jessica ;
Oppedisano, Francesca ;
Gratteri, Santo ;
Muscoli, Carolina ;
Mollace, Vincenzo .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 213 :8-14
[23]   The gut microbiota and host health: a new clinical frontier [J].
Marchesi, Julian R. ;
Adams, David H. ;
Fava, Francesca ;
Hermes, Gerben D. A. ;
Hirschfield, Gideon M. ;
Hold, Georgina ;
Quraishi, Mohammed Nabil ;
Kinross, James ;
Smidt, Hauke ;
Tuohy, Kieran M. ;
Thomas, Linda V. ;
Zoetendal, Erwin G. ;
Hart, Ailsa .
GUT, 2016, 65 (02) :330-339
[24]   Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut [J].
Michielan, Andrea ;
D'Inca, Renata .
MEDIATORS OF INFLAMMATION, 2015, 2015
[25]   Targeting IL-17and TH17 cells in chronic inflammation [J].
Miossec, Pierre ;
Kolls, Jay K. .
NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (10) :763-776
[26]   Gut microbiota and IBD: causation or correlation? [J].
Ni, Josephine ;
Wu, Gary D. ;
Albenberg, Lindsey ;
Tomov, Vesselin T. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (10) :573-584
[27]   Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol [J].
Pacher, P ;
Nivorozhkin, A ;
Szabo, C .
PHARMACOLOGICAL REVIEWS, 2006, 58 (01) :87-114
[28]   Mucosal adhesion and anti-inflammatory effects of Lactobacillus rhamnosus GG in the human colonic mucosa: A proof-of-concept study [J].
Pagnini, Cristiano ;
Corleto, Vito Domenico ;
Martorelli, Michela ;
Lanini, Claudio ;
D'Aambra, Giancarlo ;
Di Giulio, Emilio ;
Delle Fave, Gianfranco .
WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (41) :4652-4662
[29]   New Approaches for Bacteriotherapy: Prebiotics, New-Generation Probiotics, and Synbiotics [J].
Patel, Rachna ;
DuPont, Herbert L. .
CLINICAL INFECTIOUS DISEASES, 2015, 60 :S108-S121
[30]   Mechanisms of Disease: Inflammatory Bowel Diseases [J].
Ramos, Guilherme Piovezani ;
Papadakis, Konstantinos A. .
MAYO CLINIC PROCEEDINGS, 2019, 94 (01) :155-165